Gapping up
In reaction to earnings/guidance:
- None
Other news:
- MOGO +29.8% (plans to make an initial corporate investment of up to $1.5 million in bitcoin and will consider additional investments in 2021 as it monetizes its $17 million investment portfolio)
- SUPN +27% (positive results from a Phase III study of SPN-812 for ADHD)
- MGNI +20.2% (Needham analyst names MGNI as Top Pick for 2021, on CNBC)
- CASI +13.4% (announces that the Chinese Center for Drug Evaluation has granted Breakthrough Therapy Designation to its partner Juventas Cell Therapy for CNCT19, a potential CD19 CAR-T therapy for the treatment of adults with relapsed/refractory B-cell acute lymphoblastic leukemia )
- WSG +12% (announces intention to terminate ADS deposit agreement and to seek delisting of the ADSs from Nasdaq)
- OCN +10.3% (announces deal with Oaktree Capital to form strategic relationship to acquire and hold mortgage servicing rights)
- SRNE +9.3% (submitted an emergency use authorization application to the FDA for COVI-STIX rapid test for the detection of SARS-CoV-2 viral antigen)
- DQ +5% (announced that its subsidiary Xinjiang Daqo New Energy has signed long-term high-purity polysilicon supply agreements with a subsidiary of JA Solar and with another leading solar company)
- CWEN +1.4% (announces agreements providing for co-investment in a 1,204 MW portfolio of renewable energy projects)
- RGNX +1.1% (to sell a portion of its Zolgensma royalty rights for $200 mln)
- PFE +0.7% (and BioNTech (BNTX) to supply the US with 100 mln additional doses of COVID-19 vaccine)
Analyst comments:
- KLDO +13.9% (initiated with a Mkt Outperform at JMP Securities)
- LAC +8.8% (initiated with a Buy at Stifel)
- HGEN +5.8% (initiated with a Buy at National Securities)
- PCPL +2.9% (initiated with a Buy at The Benchmark Company)
- RDS.A +1.8% (initiated with a Buy at MKM Partners)